369 related articles for article (PubMed ID: 34917090)
21. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.
Lecocq Q; Zeven K; De Vlaeminck Y; Martens S; Massa S; Goyvaerts C; Raes G; Keyaerts M; Breckpot K; Devoogdt N
Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31569553
[TBL] [Abstract][Full Text] [Related]
23. The CD47-SIRPα Immune Checkpoint.
Logtenberg MEW; Scheeren FA; Schumacher TN
Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
[TBL] [Abstract][Full Text] [Related]
24. The role of cis dimerization of signal regulatory protein alpha (SIRPalpha) in binding to CD47.
Lee WY; Weber DA; Laur O; Stowell SR; McCall I; Andargachew R; Cummings RD; Parkos CA
J Biol Chem; 2010 Dec; 285(49):37953-63. PubMed ID: 20826801
[TBL] [Abstract][Full Text] [Related]
25. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.
Zhao XW; van Beek EM; Schornagel K; Van der Maaden H; Van Houdt M; Otten MA; Finetti P; Van Egmond M; Matozaki T; Kraal G; Birnbaum D; van Elsas A; Kuijpers TW; Bertucci F; van den Berg TK
Proc Natl Acad Sci U S A; 2011 Nov; 108(45):18342-7. PubMed ID: 22042861
[TBL] [Abstract][Full Text] [Related]
26. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor.
Tanaka K; Miyoshi H; Kawamoto K; Shimasaki Y; Nakashima K; Imamoto T; Yamada K; Takeuchi M; Moritsubo M; Furuta T; Kohno K; Tamura S; Sonoki T; Ohshima K
Pathology; 2024 Feb; 56(1):81-91. PubMed ID: 38110323
[TBL] [Abstract][Full Text] [Related]
28. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.
Zeven K; De Groof TWM; Ceuppens H; Awad RM; Ertveldt T; de Mey W; Meeus F; Raes G; Breckpot K; Devoogdt N
Front Immunol; 2023; 14():1268900. PubMed ID: 37799715
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47.
Hatherley D; Lea SM; Johnson S; Barclay AN
J Biol Chem; 2014 Apr; 289(14):10024-8. PubMed ID: 24550402
[TBL] [Abstract][Full Text] [Related]
30. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
31. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
Baumann N; Rösner T; Jansen JHM; Chan C; Marie Eichholz K; Klausz K; Winterberg D; Müller K; Humpe A; Burger R; Peipp M; Schewe DM; Kellner C; Leusen JHW; Valerius T
Cancer Sci; 2021 Aug; 112(8):3029-3040. PubMed ID: 34058788
[TBL] [Abstract][Full Text] [Related]
33. Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
Fournier B; Andargachew R; Robin AZ; Laur O; Voelker DR; Lee WY; Weber D; Parkos CA
J Biol Chem; 2012 Jun; 287(23):19386-98. PubMed ID: 22511785
[TBL] [Abstract][Full Text] [Related]
34. Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis.
Zheng F; Put S; Bouwens L; Lahoutte T; Matthys P; Muyldermans S; De Baetselier P; Devoogdt N; Raes G; Schoonooghe S
J Nucl Med; 2014 May; 55(5):824-9. PubMed ID: 24686780
[TBL] [Abstract][Full Text] [Related]
35. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
36. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
37. Nanobodies as tools for in vivo imaging of specific immune cell types.
De Groeve K; Deschacht N; De Koninck C; Caveliers V; Lahoutte T; Devoogdt N; Muyldermans S; De Baetselier P; Raes G
J Nucl Med; 2010 May; 51(5):782-9. PubMed ID: 20395332
[TBL] [Abstract][Full Text] [Related]
38. BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden MJ; Zwarthoff SA; Arends RJ; Reinieren-Beeren IMJ; Paradé MCBC; Driessen-Engels L; de Laat-Arts K; Damming D; Santegoeds-Lenssen EWH; van Kuppeveld DWJ; Lodewijks I; Olsman H; Matlung HL; Franke K; Mattaar-Hepp E; Stokman MEM; de Wit B; Glaudemans DHRF; van Wijk DEJW; Joosten-Stoffels L; Schouten J; Boersema PJ; van der Vleuten M; Sanderink JWH; Kappers WA; van den Dobbelsteen D; Timmers M; Ubink R; Rouwendal GJA; Verheijden G; van der Lee MMC; Dokter WHA; van den Berg TK
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37068796
[TBL] [Abstract][Full Text] [Related]
39. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT.
Vaneycken I; Govaert J; Vincke C; Caveliers V; Lahoutte T; De Baetselier P; Raes G; Bossuyt A; Muyldermans S; Devoogdt N
J Nucl Med; 2010 Jul; 51(7):1099-106. PubMed ID: 20554727
[TBL] [Abstract][Full Text] [Related]
40. SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells.
Pengam S; Durand J; Usal C; Gauttier V; Dilek N; Martinet B; Daguin V; Mary C; Thepenier V; Teppaz G; Renaudin K; Blancho G; Vanhove B; Poirier N
Am J Transplant; 2019 Dec; 19(12):3263-3275. PubMed ID: 31207067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
